Business Context and Reporting Period
Company: Passage BIO, Inc. (PASG)
Filing Type: Form 8-K (Current Report)
Date of Report: October 24, 2024
Reporting Period: Event-based report for October 24, 2024.
Context: The filing discloses a scientific presentation made by the Company at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress and the issuance of a related press release.
Key Financial Metrics
This Form 8-K is a disclosure of a non-financial event (scientific presentation) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the dissemination of scientific information regarding the Company's pipeline at the ESGCT Annual Congress.
Guidance, Outlook, and Risks
Management Commentary: The Company presented scientific data at the ESGCT 31st Annual Congress. Details of the presentation are contained in Exhibit 99.2 (ESGCT Presentation) and the press release in Exhibit 99.1.
Regulatory Note: The information in Item 7.01 and the accompanying exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Risks/Contingencies: No specific risks or contingencies are detailed in the body of this 8-K; the filing serves as a conduit for the attached scientific materials.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (ESGCT Presentation) for specific clinical data and scientific findings.
- Verify the Company's status as an Emerging Growth Company (indicated as "Yes" in the filing).
- Confirm that the scientific data presented has not been previously disclosed in other filings.
- Note that this filing does not update the Company's financial guidance or liquidity position.